Replies to post #484114 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Go buy your eli Lilly stock and we can check back in a decade how this treatment performed and compare that to where NWBO is at. :)

Have a good one TD84.

[flipper44]

The therapy you refer to is a “me too” Checkpoint Inhibitor. Several companies have run thousands of trials on this Type of CI. The reason it worked on a subtype of rectal cancer so well was specific to that subtype’s vulnerability to CIs. It’s a God send for those patients, because the surgical alternative can often mean horrible inconveniences thereafter. It will save a number of lives.

[JimSmith111]

I don't believe a well-informed NWBO investor would share your concerns, much less find the content you shared 'scary as hell.' In my opinion.

If one was not familiar with NWBO and related details and was the type of investor that is inclined to be scared of everything, it would make sense to be afraid of this article. The fear would naturally make sense, because if one isn't familiar enough with this company to realize that there is no need for fear, then fear will fill the gap that could have been filled with information.

But take the spot reserved for that fear and fill it up with NWBO-related knowledge instead, and I do not think you will find any of the content that you shared to be that concerning. At all. Whatsoever.

[rogers5729]

Yikes, I'm no fan of management, but anyone citing The Epoch Times as real news is scary enough for me...

[iwasadiver]

1. Dostarlimab’s efficacy was in colorectal cancers based on a trial of 20 people, all of whom had a poor prognostic tumor marker that only 6-10% of colorectal cancers carry. Good news but you can see the headlines is a bit exaggerated

2. The manuscript took way longer than anyone expected due to COVID, 70 authors, the authors also being extremely busy clinicians and educators, and the length of time it took to properly describe the outside comparators groups in detail.

I happen to know from an unrelated source that the manuscript was only recently finalized. We are well within the turnaround window for the peer review process right now. Relax, it’s coming

[Dan88]

It's exciting news but first you have to put thing in perspective: for this kind of cancer (localized, not yet spread) 5-year survival rate is more than 90%, and the trial has now only followed these small number of patients up to 25 months.

It's still a long road to go to see if the exciting results today can hold.

But good for them, congrats!

[Compare that to the prognosis of GBM, you know the story. Cheer]

[biosectinvestor]

It’s a PD-1 Checkpoint Inhibitor drug, which means it just turns off the cloaking that the body turns on to prevent autoimmune disease and the the tumor is already hot, so the immune system can identify the cancer and take it out.

1) likely other checkpoint inhibitors will have a similar impact for this particular cancer with these biomarkers.

2) DCVax turns on the immune system to a cancer when the cancer is NOT hot already but cold and is not being attacked by the immune system. For instance, in GBM, PD-1 and PD-L1 Checkpoint Inhibitors (CI’s) do not work. For most cancers CI’s may have some impact but often the my do not extend survival and the impact is not as dramatic.

3) this drug, being of the same nature and class as similar drugs like Keytruda, will compete with that line of drugs when that particular task is required.

More likely this drug will add to the CI’s available to combine with DCVax where immune responses subsequently trigger the relevant PD-1/PD-L1 masking of the cancer that CI’s turn off. Cancer is generally dynamic and the pathology of the disease is complex. It worked for this subset of patients, and that is great, but journalists and readers are not well informed about immunotherapies so it sounds like a miracle drug but it is doubtful that it will impact in other cancers where these very specific and narrow biomarkers are not the dominant factor.

[Evaluate]

GSK (not Eli Lilly)